EUVIMEDEUVIMED entdecken
Crossref

Germline Neurofibromin 1 mutation enhances the anti‐tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity

Wanqiao Wang, Xin Li, Xia Qin iD, Yan Miao, Yingwen Zhang, Shanshan Li, Ruen Yao, Yi Yang, Lisha Yu, Hua Zhu, Lili Song, Shengqiao Mao und 4 weitere

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18851 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Wanqiao Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Translational Medicine Institute, Department of Hematology & Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University Sc…. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Juvenile, Neurofibromatosis 1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Shanghai Municipal Education Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Juvenile myelomonocytic leukaemia (JMML) is an aggressive paediatric leukaemia characterized by mutations in five canonical RAS pathway genes, including the NF1 gene. JMML is driven by germline NF1 gene mutations, with additional somatic aberrations resulting in the NF1 biallelic inactivation, leading to disease progression. Germline mutations in the NF1 gene alone primarily cause benign neurofibromatosis type 1 (NF1) tumours rather than malignant JMML, yet the underlying mechanism remains unclear. Here, we demonstrate that with reduced NF1 gene dose, immune cells are promoted in anti‐tumour immune response. Comparing the biological properties of JMML and NF1 patients, we found that not only JMML but also NF1 patients driven by NF1 mutations could increase monocytes generation. But monocytes cannot further malignant development in NF1 patients. Utilizing haematopoietic and macrophage differentiation from iPSCs, we revealed that NF1 mutations or knockout (KO) recapitulated the classical haematopoietic pathological features of JMML with reduced NF1 gene dose. NF1 mutations or KO promoted the proliferation and immune function of NK cells and iMacs derived from iPSCs. Moreover, NF1 ‐mutated iNKs had a high capacity to kill NF1 ‐KO iMacs. NF1 ‐mutated or KO iNKs administration delayed leukaemia progression in a xenograft animal model. Our findings demonstrate that germline NF1 mutations alone cannot directly drive JMML development and suggest a potential cell immunotherapy for JMML patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, JuvenileNeurofibromatosis 1AnimalsHumansNeurofibromin 1Genes, Neurofibromatosis 1Germ-Line MutationMutationImmunityGerm Cells

Stichwörter der Autor:innen

NF1JMMLdifferentiationgermline mutationinduced pluripotent stem cells

Substanzen

Neurofibromin 1

Autor:innen und Institutionen

  • Pediatric Translational Medicine Institute, Department of Hematology & Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Key Laboratory of Pediatric Hematology & Oncology of…
  • Department of Endocrinology and Metabolism, Shanghai Children's Medical Center, Shanghai, China.
  • Department of Hematology & Oncology, Shanghai Children's Medical Center, Shanghai, China.
  • State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Medical Genetics, Shanghai Children's Medical Center, Shanghai, China.

ORCID-Profile: Xia Qin, Yanxin Li

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Municipal Education Commission
  • Natural Science Foundation of Shanghai

Zitieren

APA

Wang, W., Li, X., Qin, X., Miao, Y., Zhang, Y., Li, S., Yao, R., Yang, Y., Yu, L., Zhu, H., Song, L., Mao, S., Wang, X., Chen, J., Feng, H., & Li, Y. (2023). Germline Neurofibromin 1 mutation enhances the anti‐tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity. British Journal of Haematology. https://doi.org/10.1111/bjh.18851

Vancouver

Wang W, Li X, Qin X, Miao Y, Zhang Y, Li S, et al. Germline Neurofibromin 1 mutation enhances the anti‐tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity. British Journal of Haematology. 2023. doi:10.1111/bjh.18851

BibTeX
@article{Wang2023,
  author = {Wang, Wanqiao and Li, Xin and Qin, Xia and Miao, Yan and Zhang, Yingwen and Li, Shanshan and Yao, Ruen and Yang, Yi and Yu, Lisha and Zhu, Hua and Song, Lili and Mao, Shengqiao and Wang, Xiumin and Chen, Jing and Feng, Haizhong and Li, Yanxin},
  title = {Germline Neurofibromin 1 mutation enhances the anti‐tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18851}
}
Kostenlos starten →